2019年冠状病毒病爆发(COVID-19),由严重急性呼吸综合征冠状病毒2(SARS-COV-2)引起,产生了前所未有的全球卫生和社会紧急情况。尽管临床医生为开发有效的抗COVID-19治疗方案做出了许多努力,目前尚无特定的治疗方法.在抗病毒药物中,在重症COVID-19患者中首次出现阳性报告后,康复患者的恢复期血浆(CP)是深入研究的对象。被动免疫疗法为体液免疫缺陷的COVID-19患者提供更高益处的基本原理,比如那些患有实体和血液癌症的人,患有原发性和获得性免疫缺陷的患者,以及实体器官和造血干细胞移植的接受者。这篇叙述性综述的目的是批判性地讨论在这些类别的患者中使用CP的文献证据。
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), generated an unprecedented global health and social emergency. Despite many efforts from clinicians to develop effective anti-COVID-19 treatment protocols, no specific therapy is currently available. Among anti-viral agents, convalescent plasma (CP) from recovered patients is the object of intense research following the first positive reports in severe COVID-19 patients. Passive immunotherapy the rationale to provide higher benefits in COVID-19 patients with humoral immune deficiencies, such as those with solid and hematologic cancers, patients with primary and acquired immunodeficiencies, and recipients of solid organ and hematopoietic stem cell transplants. The aim of this narrative
review will be to critically discuss the literature evidence on CP use in these categories of patients.